Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The type IV polymorph of KEu(PO(3))(4).

ABSTRACT: Single crystals of KEu(PO(3))(4), potassium europium(III) polyphosphate, were obtained by solid-state reactions. This monoclinic form is the second polymorph described for this composition and belongs to type IV of long-chain polyphosphates with general formula A(I)B(III)(PO(3))(4). It is isotypic with its KEr(PO(3))(4) and KDy(PO(3))(4) homologues. The crystal structure is built of infinite helical chains of corner-sharing PO(4) tetra-hedra with a repeating unit of eight tetra-hedra. These chains are further linked by isolated EuO(8) square anti-prisms, forming a three-dimensional framework. The K(+) ions are located in pseudo-hexa-gonal channels running along [01] and are surrounded by nine O atoms in a distorted environment.

SUBMITTER: Oudahmane A

PROVIDER: S-EPMC2972142 | biostudies-literature | 2009 Nov

REPOSITORIES: biostudies-literature

ACCESS DATA

Json Xml

Publications

The type IV polymorph of KEu(PO(3))(4).

Oudahmane Abdelghani A Daoud Mohamed M Tanouti Boumediene B Avignant Daniel D Zambon Daniel D

Acta crystallographica. Section E, Structure reports online 20091121 Pt 12

Single crystals of KEu(PO(3))(4), potassium europium(III) polyphosphate, were obtained by solid-state reactions. This monoclinic form is the second polymorph described for this composition and belongs to type IV of long-chain polyphosphates with general formula A(I)B(III)(PO(3))(4). It is isotypic with its KEr(PO(3))(4) and KDy(PO(3))(4) homologues. The crystal structure is built of infinite helical chains of corner-sharing PO(4) tetra-hedra with a repeating unit of eight tetra-hedra. These chai ...[more]

PMID: 21578546

Similar Datasets

A monoclinic polymorph of KY(PO(3))(4).

Project description:The title compound, potassium yttrium polyphosphate, KY(PO(3))(4), was synthesized using the flux method. The atomic arrangement consists of an infinite long-chain polyphosphate organization. Chains, with a period of four PO(4) tetra-hedra, run along the a-axis direction. Two other polymorphs of this phosphate are known, in space groups P21/n and C2/c.

| S-EPMC2961604 | biostudies-literature

A new polymorph of Lu(PO(3))(3).

Project description:A new polymorph of lutetium polyphosphate, Lu(PO(3))(3), was found to be isotypic with the trigonal form of Yb(PO(3))(3). Two of the three Lu atoms occupy special positions (Wyckoff positions 3a and 3b, site symmetry ). The atomic arrangement consists of infinite helical polyphosphate chains running along the c axis, with a repeat period of 12 PO(4) tetra-hedra, joined with LuO(6) octa-hedra.

| S-EPMC2961903 | biostudies-literature

A second polymorph with composition Co(3)(PO(4))(2)·H(2)O.

Project description:Single crystals of Co(3)(PO(4))(2)·H(2)O, tricobalt(II) bis-[ortho-phosphate(V)] monohydrate, were obtained under hydro-thermal conditions. The compound is the second polymorph of this composition and is isotypic with its zinc analogue, Zn(3)(PO(4))(2)·H(2)O. Three independent Co(2+) cations are bridged by two independent orthophosphate anions. Two of the metal cations exhibit a distorted tetra-hedral coordination while the third exhibits a considerably distorted [5 + 1] octa-hedral coordination environment with one very long Co-O distance of 2.416?(3)?Å. The former cations are bonded to four different phosphate anions, and the latter cation is bonded to four anions (one of which is bidentate) and one water mol-ecule, leading to a framework structure. Additional hydrogen bonds of the type O-H?O stabilize this arrangement.

| S-EPMC2959276 | biostudies-other

Potassium ditin(IV) tris-[phosphate(V)], KSn(2)(PO(4))(3).

Project description:The title compound, KSn(2)(PO(4))(3), belongs to the NASICON-type family of phosphates with the space group R[Formula: see text]. Its structure is constructed by very regular [with P-O distances ranging from 1.513 (6) to 1.522 (6) Å] PO(4) tetra-hedra and SnO(6) octa-hedra on the 3. axis, which are linked by O atoms, forming an [Sn(2)(PO(4))(3)] framework. The K atoms occupy the [Formula: see text]. axis sites and are located in the voids of this arrangement. The crystal studied was a merohedral twin with twin law (010 100 00[Formula: see text]) and a component ratio of 0.580 (7):0.420 (7).

| S-EPMC3201389 | biostudies-literature

Monoclinic polymorph of chlorido-(dimethyl sulfoxide-κO)tri-phenyl-tin(IV).

Project description:The crystal structure of the title tin complex, [Sn(C6H5)3Cl(C2H6OS)], (I), has been reported with one mol-ecule in the asymmetric unit in an ortho-rhom-bic cell [Kumar et al. (2009 ▸). Acta Cryst. E65, m1602-m1603]. While using SnPh3Cl as a starting material for a reaction for which the products were recrystallized over a very long time (six months) from dimethyl sulfoxide (DMSO), a new polymorph was obtained for (I), with two independent mol-ecules in the asymmetric unit of a monoclinic cell. The coordination geometry of the Sn centres remains unchanged, with the Cl- ion and the DMSO mol-ecule in the apical positions and the phenyl C atoms in the equatorial positions of a trigonal bipyramid. The main difference between the polymorphs is the relative orientation of the phenyl rings in the equatorial plane, reflecting a degree of free rotation of these groups about their Sn-C bonds. In the crystal, mol-ecules are linked into [010] chains mediated by weak C-H⋯O inter-actions.

| S-EPMC5956328 | biostudies-literature

Efficacy and safety of IV/PO moxifloxacin and IV piperacillin/tazobactam followed by PO amoxicillin/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study.

Project description:ObjectiveThe aim was to compare the efficacy and safety of two antibiotic regimens in patients with diabetic foot infections (DFIs).MethodsData of a subset of patients enrolled in the RELIEF trial with DFIs requiring surgery and antibiotics were evaluated retrospectively. DFI was diagnosed on the basis of the modified Wagner, University of Texas, and PEDIS classification systems. Patients were randomized to receive either intravenous/oral moxifloxacin (MXF, N = 110) 400 mg q.d. or intravenous piperacillin/tazobactam 4.0/0.5 g t.d.s. followed by oral amoxicillin/clavulanate 875/125 mg b.d. (PIP/TAZ-AMC, N = 96), for 7-21 days until the end of treatment (EOT). The primary endpoint was clinical cure rates in the per-protocol (PP) population at the test-of-cure visit (TOC, 14-28 days after EOT).ResultsThere were no significant differences between the demographic characteristics of PP patients in either treatment group. At TOC, MXF and PIP/TAZ-AMC had similar efficacy in both the PP and intent-to-treat (ITT) populations: MXF: 76.4 % versus PIP/TAZ-AMC: 78.1 %; 95 % confidence interval (CI) -14.5 %, 9.0 % in the PP population; MXF: 69.9 % versus PIP/TAZ-AMC: 69.1 %; 95 % CI -12.4 %, 12.1 % in the ITT population. The overall bacteriological success rates were similar in both treatment groups (MXF: 71.7 % versus PIP/TAZ-AMC: 71.8 %; 95 % CI -16.9 %, 10.7 %). A similar proportion of patients (ITT population) experienced any adverse events in both treatment groups (MXF: 30.9 % versus PIP/TAZ-AMC: 31.8 %, respectively). Death occurred in three MXF-treated patients and one PIP/TAZ-AMC-treated patient; these were unrelated to the study drugs.ConclusionMoxifloxacin has shown favorable safety and efficacy profiles in DFI patients and could be an alternative antibiotic therapy in the management of DFI.Clinical trialNCT00402727.

| S-EPMC3566391 | biostudies-literature

Dichloridobis(pyridine-2-thiol-ato-κ²N,S)tin(IV): a new polymorph.

Project description:The title compound, [SnCl₂(C₅H₄NS)₂], is the product of reaction of 2,2'-dipyridyl disulfide with tin tetra-chloride. The Sn(IV) atom adopts a distorted octa-hedral geometry, with the two bidentate pyridine-2-thiol-ate ligands forming two planar four-membered chelate rings. The two Sn-Cl, two Sn-N and two Sn-S bonds are in cis, cis and trans configurations, respectively. The crystal grown from acetonitrile represents a new monoclinic polymorph in space group C2/c with the mol-ecule having twofold rotational symmetry, the Sn(IV) atom lying on the twofold axis. The mol-ecular structure of the monoclinic polymorph is very close to that of the triclinic polymorph studied previously in space group P-1, the mol-ecule occupying a general position [Masaki & Matsunami (1976 ▶). Bull. Chem. Soc. Jpn, 49, 3274-3279; Masaki et al. (1978 ▶). Bull. Chem. Soc. Jpn, 51, 3298-3301]. Apparently, the formation of the two polymorphs is determined by the different systems of inter-molecular inter-actions. In the crystal of the monoclinic polymorph, mol-ecules are bound into ribbons along the c axis by C-H⋯Cl hydrogen bonds, whereas in the crystal of the triclinic polymorph, mol-ecules form chains along the a axis by attractive S⋯S inter-actions. The crystal studied was a pseudo-merohedral twin; the refined BASF value is 0.221 (1).

| S-EPMC3393155 | biostudies-literature

RbSn(2)(PO(4))(3), a NASICON-type phosphate.

Project description:The title compound, rubidium ditin(IV) tris-(phosphate), RbSn(2)(PO(4))(3), belongs to the NASICON-type family of phosphates and crystallizes in the space group R[Formula: see text]. The structure is composed of PO(4) tetra-hedra (1 symmetry) and two slightly distorted SnO(6) octa-hedra, both with 3. symmetry, which are inter-linked through corner-sharing O atoms to form a (3) (?)[Sn(2)(PO(4))(3)](-) framework. The Rb(+) cations are located on threefold inversion axes in the voids of this framework and exhibit a coordination number of 12. The crystal studied was twinned by merohedry with a component ratio of 0.503:0.497.

| S-EPMC3089237 | biostudies-literature

NASICON-type Na(3)V(2)(PO(4))(3).

Project description:Single crystals of the title compound, tris-odium divanadium(III) tris-(orthophosphate), were grown from a self-flux in the system Na(4)P(2)O(7)-NaVP(2)O(7). Na(3)V(2)(PO(4))(3) belongs to the family of NASICON-related structures and is built up from isolated [VO(6)] octa-hedra (3. symmetry) and [PO(4)] tetra-hedra (.2 symmetry) inter-linked via corners to establish the framework anion [V(2)(PO(4))(3)](3-). The two independent Na(+) cations are partially occupied [site-occupancy factors = 0.805?(18) and 0.731?(7)] and are located in channels with two different oxygen environments, viz sixfold coordination for the first (. symmetry) and eightfold for the second (.2 symmetry) Na(+) cation.

| S-EPMC2979857 | biostudies-other

A new langbeinite-type phosphate: K(2)AlSn(PO(4))(3).

Project description:Single crystals of the title compound, dipotassium aluminium tin(IV) tris-[phosphate(V)], K(2)AlSn(PO(4))(3), were synthesized by a high temperature reaction in a platinum crucible. In the structure, the Al(III) and Sn(IV) atoms occupy the same site on a threefold rotation axis with occupational disorder in a 1:1 ratio. In the three-dimensional structure, Al/SnO(6) octa-hedra and PO(4) tetra-hedra are inter-connected via their vertices, yielding a [Al/SnP(3)O(12)](n) framework. The K atoms (site symmetry 3) reside in the large cavities delimited by the [Al/SnP(3)O(12)](n) framework, and are surrounded by 12 O atoms.

| S-EPMC3201338 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data